Musculoskeletal oncology - Advances in cytogenetics and molecular genetics and their clinical implications

Acta Oncologica

Volumn 36, Issue 3, 1997, Pages 245-254

  Choong, Peter F M ^a,b   Rydholm, Anders ^a   Mertens, Fredrik ^a   Mandahl, Nils ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CLINICAL TRIAL; HUMAN; HUMAN CELL; MOLECULAR GENETICS; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0030916066     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869709001258     Document Type: Review

References (120)

1. Enzinger FM, Weiss SW. Soft tissue tumors. Third edition. St. Louis. Mo: CV Mosby, 1995: 1-16.
2. Schajowicz F. Tumors and tumorlike lesions of bone. Second edition. Berlin: Springer-Verlag, 1994: 1-27.
3. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand 1994; 65: 1-31.
4. Fletcher CDM. Introduction. In: Fletcher CDM, and McKee PH, eds, Pathobiology of soft tissue tumors. Edinburgh: Churchill Livingstone, 1990: 1-7.
5. Fletcher CD. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 1992; 16: 213-28.
6. Weh HJ, Hossfeld DK. Systemic therapy of disseminated soft tissue sarcomas. In: Bamberg M, Hoffmann W, Hossfeld DK. eds. Recent results in cancer research. Berlin: Springer-Verlag, 1995: 147-59.
7. Bramwell V, Rouesse J, Steward W, et al. Adjuvant CY-VADIC chemotherapy for adult soft tissue sarcoma-reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994; 12: 1137-49.
8. Benjamin RS. Adjuvant chemotherapy of soft tissue sarcomas in North America. In: Bamberg M, Hoffman W, Hossfeld DK, eds. Recent results in cancer research. Berlin: Springer-Verlag, 1995: 139-45.
9. Sandberg AA, Turc-Carel C. The cytogenetics of solid tumors. Relation to diagnosis, classification and pathology. Cancer 1987; 59: 387-95.
10. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8.
11. Boveri T. Zur Frage der Enststehung maligner Tumoren. Gustav Fisher Verlag, 1914.
12. Culver KW, Vickers TM, Lamsam JL, Walling HW, Seregina T. Gene therapy for solid tumors. Br Med Bull 1995; 51: 192-204.
13. Boveri T. The origin of malignant tumours. Baltimore: The Williams and Wilkins Co., 1929: 26-7.
14. Aisenberg AC. New genetics of Burkitt's lymphoma and other non-Hodgkin's lymphoma. Am J Med 1984; 77: 1083-90.
15. Knudson AG. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-38.
16. Friend SH, Bernards R, Rogelj S. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643-6.
17. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85: 1121-8.
18. Abramson DH, Ellsworth RM, Kitchin FD, Tung G. Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced? Opthalmology 1984; 91: 1351-5.
19. Schimke RN, Lowman JT, Cowan AB. Retinoblastoma, and osteogenic sarcoma in siblings. Cancer 1974; 34: 2077-9.
20. Lee, W-H Shew JY, Hong F, et al. The retinoblastoma susceptibility gene product is a nuclear phosphoprotein associated with DNA binding activity. Nature 1987; 329: 642-5.
21. Chellappan SP, Hiebert S, Mudryi M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65: 1053-61.
22. Robbins PD, Horowitz JM, Mulligan RC. Negative regulation of human c-fos expression by the retinoblastoma gene product. Nature 1990; 346: 668-71.
23. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 1991; 88: 7605-9.
24. Hansen MF, Xu HJ, Zhao J, Hu SX, Raymond AK, Benedict WF. Expression patterns of the retinoblastoma susceptibility gene in conventional and variant histology osteosarcoma. In: Novak JF, McMaster JH, eds. Frontiers of osteosarcoma research. Interdisciplinary survey of clinical and research advances. Seattle: Hogrefe and Huber, 1993: 347-57.
25. Araki N, Atsumasa U, Kimura T, et al. Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft tissue tumors. Clin Orthop 1991; 270: 271-7.
26. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261-3.
27. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-6.
28. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995; 13: 1009-22.
29. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
30. Karp JE, Broder S. Molecular foundations of cancer: New targets for intervention. Nat Med 1995; 1: 309-20.
31. Toguchida J, Yamaguchi T, Ritchie B, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992; 52: 6194-9.
32. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54: 794-9.
33. Miller C, Aslo A, Tsay C, et al. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 1990; 50: 7950-4.
34. Birch JM. Li-Fraumeni syndrome. Eur J Cancer 1994; 30A: 1935-41.
35. Li FP, Fraumeni JF. Prospective study of a family cancer syndrome. JAMA 1982; 247: 2692-4.
36. Toguchida J. Clinical relevance of tumor suppressor gene mutations in osteosarcoma. In: Novak JF, McMaster JH, eds. Frontiers of osteosarcoma research. Interdisciplinary survey of clinical research. Seattle: Hogrefe and Huber, 1993: 337-57.
37. Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS, Kotoura Y, Yamamuro T. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 1993; 68: 1134-9.
38. Andreassen Å, Øyjord T, Hovig E et al.p53 abnormalities in different subtypes of human sarcomas. Cancer Res 1993; 53: 468-71.
39. Leach FS, Tokino T, Meltzer P, et al. P53 mutation and MDM2 amplification in human soft tissue sarcoma. Cancer Res 1993; 53: 2231-4.
40. Rowley JD. The Philadelphia chromosome translocation - A paradigm for understanding leukemia. Cancer 1990; 65: 2178-84.
41. Turc-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. 1. An evaluation of 85 cases and remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988; 32: 229-38.
42. Squire J, Zielenska M, Thorner P, et al. Variant translocations of chromosome 22 in Ewing's sarcoma. Genes Chromosom Cancer 1993; 8: 190-4.
43. Sorensen PHB, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6: 146-51.
44. Jeon I-S, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETVI. Oncogene 1995; 10: 1229-34.
45. Mugneret F, Lizard S, Aurias A, Ture-Carel C. Chromosomes in Ewing's sarcoma. II Nonrandom additional changes, trisomy 8 and der(16)t(1;16). Cancer Genet Cytogenet 1988; 32: 239-45.
46. Ladanyi L, Heinemann FS, Huvos AG, Rao PH, Chen QG, Jhanwar SC. Neural differentiation in small round cell tumors of bone and soft tissue with the translocation t(11;22)(q24;q12): an immunohistochemical study of 11 cases. Hum Pathol 1990; 21: 1245-51.
47. Kees UR, Rudduck C, Ford J, et al. Two malignant peripheral neuroepithelial tumor cell lines established from consecutive samples of one patient. Genes Chromosom Cancer 1992; 4: 195-204.
48. Zucman J, Delattre O, Desmaze C, et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosom Cancer 1992; 5: 271-7.
49. Whang-Peng J, Freter CE, Knutsen T, Nanfro JJ, Gazdar A. Translocation t(11;22) in esthesioneuroblastoma. Cancer Genet Cytogenet 1987; 29: 155-7.
50. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162-5.
51. May WA, Gishizky ML, Lessniek SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA binding domain encoded by FLI-1 for transformation. Proc Natl Acad Sci USA 1993; 90: 5752-6.
52. Eneroth M, Mandahl N, Heim S, et al. Localisation of the chromosomal breakpoints of the t(12;16) in liposarcoma to subbands 12q13.3 and 16p11.2. Cancer Genet Cytogenet 1990; 48: 101-7.
53. Turc-Carel C, Limon J, Dal-Cin P, Rao U, Karakousis C, Sandberg AA. Cytogenetic studies of adipose tumors. II. Recurrent reciprocal translocation t(12;16)(q13;p11) in myxoid liposarcoma. Cancer Genet Cytogenet 1986; 23: 291-9.
54. Sreekantaiah C, Karakousis CP, Leong SPL, Sandberg AA. Cytogenetic findings in liposarcoma correlate with histopathologic subtypes. Cancer 1992; 69: 2484-95.
55. Pedeutour F, Suijkerbuijk RF, Van Gaal J, et al. Chromosome 12 origin in rings and giant markers in well-differentiated liposarcoma. Cancer Genet Cytogenet 1993; 66: 133-4.
56. Pedeutour F, Suijkerbuijk RF, Forus A, et al. Complex composition and coamplification of SAS and MDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcoma. Genes Chromosom Cancer 1994; 10: 85-94.
57. Rabbitts TH, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993; 4: 175-80.
58. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993; 363: 640-4.
59. Ron D, Habener JF. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C EBP and LAP and functions as a dominant negative inhibitor of gene transcription. Genes Dev 1992; 6: 439-45.
60. Limon J, Mrozek K, Mandahl N, et al. Cytogenetics of synovial sarcoma: presentation of ten new cases and review of the literature. Genes Chromosom Cancer 1991; 3: 338-45.
61. Enzinger FM, Weiss SW. Synovial sarcoma. In: Soft tissue tumors. Third edition. St. Louis, MO: CV Mosby, 1995: 757-86.
62. Mandahl N, Limon J, Mertens F, et al. Nonrandom secondary chromosome aberrations in synovial sarcomas with t(X;18). Int J Oncol 1995; 7: 495-9.
63. Clark J, Rocques PJ, Crew AJ, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994; 7: 502-8.
64. de Leeuw B, Balemans M, Weghuis DO, et al. Molecular cloning of the synovial sarcoma-specific translocation (X;18) (p11.2;q11.2) breakpoint. Hum Mol Genet 1994; 3: 745-9.
65. Smith S, Reeves BR, Wong L, Fisher C. A consistent chromosomal translocation in synovial sarcomas. Cancer Genet Cytogenet 1987; 26: 179-80.
66. Enzinger FM, Weiss SW. Rhabdomyosarcoma. Soft tissue tumors. Third edition. St. Louis, MO: CV Mosby, 1995: 539-78.
67. Douglas EC, Shapiro DN, Valentine M, et al. Alveolar rhabdomyosarcoma with the t(2;13) cytogenetic findings and clinicopathologic correlations. Med Pediatr Oncol 1993; 21: 83-7.
68. Whang-Peng J, Knutsen T, Horowitz ME, Triche TJ. Cytogenetic studies in subgroup of rhabdomyosarcoma. Genes Chromosom Cancer 1992; 5: 299-310.
69. Biegel JA, Meek RS, Parmiter AH, Conrad K, Emanuel BS. Chromosome translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma. Genes Chromosom Cancer 1991; 3: 483-4.
70. Douglas EC, Rowe ST, Valentine M, et al. Variant translocations of chromosome 13 in alveolar rhabdomyosarcoma. Genes Chromosom Cancer 1991; 3: 480-2.
71. Fletcher JA, Kozakewich HP, Pavelka K, et al. Consistent cytogenetic aberrations in hepatoblastoma: a common pathway of genetic alterations in embryonal liver and skeletal muscle malignancies? Genes Chromosom Cancer 1991; 3: 37-43.
72. Koufos A, Grundy P, Morgan K, et al. Familial Wiedemann-Beckwith syndrome and a second Wilms|apos tumor locus both map to 11p15.5. Am J Hum Genet 1989; 44: 711-9.
73. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993; 5: 230-5.
74. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rearrangement of the PAX3 paired box gene in the paediatric solid tumor alveolar rhabdomyosarcoma. Nat Genet 1993; 3: 113-7.
75. Burri M, Tromvoukis Y, Bopp D, Frigerio G, Noll M. Conservation of the paired domain in metazoans and its structure in three isolated human genes. EMBO J 1989; 8: 1183-90.
76. Goulding MD, Chalepakis G, Deutsch U, Erselius JR, Gruss P. Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. EMBO J 1991; 10: 1135-47.
77. Sasaki H, Hogan BLM. Differential expression of multiple fork head related genes during gastrulation and axial pattern formation in the mouse embryo. Development 1993; 118: 47-59.
78. Hacker U, Grossniklaus U, Gehring WJ, Jackle H. Developmentally regulated Drosophila gene family encoding the forkhead domain. Proc Nat Acad Sci USA 1992; 89: 8754-8.
79. Li J, Vogt PK. The retroviral oncogene qin belongs to the transcription factor family that includes the homeotic gene fork head. Proc Natl Acad Sci USA 1993; 90: 4490-4.
80. Clevidence DE, Overdier DG, Tao W, et al. Identification of nine tissue-specific transcription factors of the hepatocyte nuclear factor 3/forkhead DNA-binding domain family. Proc Natl Acad Sci USA 1993; 90: 3948-52.
81. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994; 54: 2869-72.
82. Davis RJ, Bennicelli JL, Macina RA, Nycum LM, Biegel JA, Barr FG. Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma. Hum Mol Genet 1995; 4: 2355-62.
83. Fletcher JA. Translocation (12;22)(q13-14;q12) is a non-random aberration in soft tissue clear-cell sarcoma. Genes Chromosom Cancer 1992; 5: 184.
84. Peulve P, Michot C, Vannier J-P, Tron P, Hemet J. Clear cell sarcoma with t(12;22)(q13-14;q12). Genes Chromosom Cancer 1991; 3: 400-2.
85. Kindblom, L-G, Lodding P, Angervall A. Clear-cell sarcoma of tendons and aponeurones. An immunohistochemical and electron microscopic analysis indicating neural crest origin. Virchows Arch Pathol Anal 1983; 409: 109-28.
86. Stenman G, Andersson H, Mandahl N, Meis-Kindblom JM, Kindblom. L-G. Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. Int J Cancer 1995; 62: 398-402.
87. Örndal C, Carlén B, Åkerman M, et al. Chromosomal abnormality t(9;22)(q22;q12) in an extraskeletal myxoid chondrosarcoma characterized by fine needle aspiration cytology, electron microscopy, immunohistochemistry and DNA flow cytometry. Cytopathology 1991; 2: 261-70.
88. Labelle Y, Zucman J, Stenman G, et al. Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum Mol Genet 1995; 4: 2219-26.
89. Gill S, McManus AP, Crew AJ, et al. Fusion of the EWS gene to a segment from 9q22-31 in a human myxoid chondrosarcoma. Genes Chromosom Cancer 1995; 12: 307-10.
90. Mandahl N, Heim S, Willén H, et al. Characteristic karyotypic anomalies identify subtypes of malignant fibrous histiocytoma. Genes Chromosom Cancer 1989; 1: 9-14.
91. Rydholm A, Mandahl N, Heim S, Kreicbergs A, Willén H, Mitelman F. Malignant fibrous histiocytomas with a 19p+ marker chromosome have increased relapse rate. Genes Chromosom Cancer 1990; 2: 296-9.
92. Nilbert M, Rydholm A, Willén H, Mitelman F, Mandahl N. MDM2 gene amplification correlates with ring chromosomes in soft tissue tumors. Genes Chromosom Cancer 1994; 9: 261-5.
93. Mitelman F. Catalog of chromosome aberrations in cancer. Fifth ed. New York: Wiley-Liss, 1994.
94. Choong PFM, Mandahl N, Mertens F, et al. 19p+ marker chromosome correlates with relapse in malignant fibrous histiocytoma. Genes Chromosom Cancer 1996; 16: 88-93.
95. Hoogerwerf WA, Hawkins AL, Perlman EJ, Griffin CA. Chromosome analysis of nine osteosarcomas. Genes Chromosom Cancer 1994; 9: 88-92.
96. Biegel JA, Womer RB, Emanuel BS. Complex karyotypes in a series of pediatric osteosarcomas. Cancer Genet Cytogenet 1989; 38: 89-100.
97. Mertens F, Mandahl N, Örndal C, et al. Cytogenetic findings in 33 osteosarcomas. Int J Cancer 1993; 55: 44-50.
98. Örndal C, Mandahl N, Rydholm A, Willén H, Brosjö O, Mitelman F. Chromosome aberrations and cytogenetic intratumor heterogeneity in chondrosarcomas. J Cancer Res Clin Oncol 1993; 120: 51-6.
99. Mandahl N, Heim S, Arheden K, Rydholm A, Willén H, Mitelman F. Chromosomal rearrangements in chondromatous tumors. Cancer 1990; 65: 242-8.
100. Nilbert M, Rydholm A, Mitelman F, Meltzer PS, Mandahl N. Characterization of the 12q13 15 amplicon in soft tissue tumors. Cancer Genet Cytogenet 1995; 83: 32-6.
101. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993; 53: 16-8.
102. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-3.
103. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wildtype p53 activity. EMBO J 1993; 12: 461-8.
104. Pedeutour F, Simon M-P, Minoletti F, et al. Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res 1995; 55: 2400-3.
105. Kampe CE, Rosen G, Eilber G, et al. Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localised disease. Cancer 1993; 72: 2161-9.
106. Bridge JA, Neff JR, Mouron BJ. Giant cell tumor of bone: chromosomal analysis of 48 specimens and review of the literature. Cancer Genet Cytogenet 1992; 58: 2-13.
107. Örndal C, Mandahl N, Rydholm A, et al. Supernumerary ring chromosomes in five bone and soft tissue tumors of low or borderline malignancy. Cancer Genet Cytogenet 1992; 60: 170-5.
108. Fletcher CDM, Åkerman M, Dal Cin P, et al. Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) collaborative study group. Am J Pathol 1995; 148: 623-30.
109. Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop 1986; 204: 9-24.
110. Alvegård TA, Berg NO, Baldetorp B, et al. Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. J Clin Oncol 1990; 8: 538-47.
111. Choong PFM, Åkerman M, Willen H, et al. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotype-specific? APMIS 1995; 103: 797-805.
112. Choong PFM, Åkerman M, Willén H, et al. Prognostic value of Ki-67 expression in 182 soft tissue sarcomsa. Proliferation - a marker of metastasis? APMIS 1994; 102: 915-24.
113. Choong PFM, Gustafson P, Willén H, et al. Prognosis following locally recurrent soft-tissue sarcoma. A staging system based on primary and recurrent tumor characteristics. Int. J. Cancer 1995; 60: 33-7.
114. Mandahl N, Heim S, Arheden K, Rydholm A, Willén H, Mitelman F. Three major cytogenetic subgroups can be identified among chromosomally abnormal solitary lipomas. Hum Genet 1988; 79: 203-8.
115. Bridge JA, Bhatia PS, Anderson JR, Neff JR. Biologic and clinical significance of cytogenetic and molecular cytogenetic abnormalities in benign and malignant cartilaginous lesions. Cancer Genet Cytogenet 1993; 69: 79-90.
116. Patel SR, Burgess MA, Plager C, Papadopoulos NE, Linke KA, Benjamin RS. Myxoid liposarcoma. Experience with chemotherapy. Cancer 1994; 74: 1265-9.
117. Yandell DW, Campbell TA, Dayton AH, et al. Oncogenic point mutations in the human retinoblastoma gene: their appplication to genetic counseling. N Engl J Med 1989; 321: 1689-95.
118. Wunder JS, Czitrom AA, Kandel R, Andrulis IL. Analysis of alterations in retinoblastoma gene and tumor grade in bone and soft tissue sarcomas. J Natl Cancer Inst 1991; 83: 194-200.
119. Cance WG, Brennan MF, Dudas ME, Huang C-M, Cordoncardo C. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 1990; 323: 1457-62.
120. Skuse GR, Ludlow JW. Tumor suppressor genes in disease and therapy. Lancet 1995; 345: 902-6.